Welcoming the recent success of Pfizer’s rheumatoid arthritis treatment, Xeljanz, into China.
Xeljanz, also known as tofacitinib or ‘Xeloda’, is a medication used for the treatment of rheumatoid arthritis. It was approved by the FDA in December 2011 and has since been marketed worldwide under many brand names including Xeljanz, Rixume, Cozaar, Zyvox.
The “xeljanz cost” is a medication that can be used to treat rheumatoid arthritis. The medication has been in use since 2005, but it was only approved in 2016.
The medicine Xeljanz (tofacitinib) from Pfizer is used to treat arthritis and ulcerative colitis. Xeljanz aids in the regulation of immune system activity, which may benefit persons with chronic inflammatory disorders. The medicine has been on the market since 2012, and FDA permission for additional applications is still being sought.
However, as the number of Xeljanz indications expands, so does awareness of the drug’s potentially fatal adverse effects. Xeljanz has been linked to an increased risk of blood clots, heart issues, cancer, and even death, according to FDA safety advisories issued in recent years. For the numerous patients who took Xeljanz without knowing about the hazards, these cautions may be too little, too late. Some patients are suing Pfizer, alleging that the corporation created a flawed medicine and failed to properly warn about the dangers of significant, perhaps fatal adverse effects.
If you took Xeljanz and developed a cancer, a heart condition, or thrombosis, you may be able to file a case. These cases are being reviewed for free by our nationally known dangerous-drug lawyers, who will take them on a contingency-fee basis. Use our online contact form to get a free case evaluation.
What is the purpose of Xeljanz?
Since its first approval in 2012 for adults with rheumatoid arthritis, Xeljanz has been prescribed for over ten years. In 2017, Xeljanz was licensed to treat adults with psoriatic arthritis, and in 2018, it was approved to treat adults with ulcerative colitis. Xeljanz was authorized in 2020 to treat polyarticular juvenile idiopathic arthritis in children aged 2 and above. Xeljanz is the first and only JAK inhibitor licensed for three adult diseases, according to the drug’s official website.
What Is Xeljanz and How Does It Work?
The major active element of Xeljanz, tofacitinib, operates by lowering immune system activity. Rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis are all caused by an overactive immune system.
Xeljanz is a Janus kinase (JAK) inhibitor that reduces cytokine production in the body. Cytokines are signaling proteins that have a role in immune system regulation. In response to infections, the body’s production of cytokines rises on occasion. The body’s defensive reaction to infection is inflammation. The body may produce too many cytokines in persons with chronic inflammatory diseases like rheumatoid arthritis and ulcerative colitis.
Xeljanz reduces chronic inflammation and related symptoms by inhibiting or blocking the production of cytokines in the JAK signal pathway. It’s usually given to chronic inflammatory patients who haven’t gotten relief from other medications that are usually used as a first line of defense.
How much money does Pfizer put into Xeljanz marketing?
There are a lot of rivals for Xeljanz, especially in the treatment of rheumatoid arthritis. By 2027, the worldwide market for RA medications is predicted to have grown to approximately $63 billion, up from $58 billion in 2019.
Advertising investment is driven by the fierce rivalry for market share. Pfizer spends about $100 million per year on Xeljanz advertising, which includes digital, print, and national television commercials. According to Fierce Pharma, Pfizer spent $27.6 on Xeljanz TV advertisements in December 2020 alone. That was less than a month before new safety data revealed that Xeljanz might raise the risk of major cardiac issues and cancer.
What Are Xeljanz’s Most Common Side Effects?
Xeljanz may cause the following adverse effects:
- Infection of the upper respiratory tract (such as the common cold)
- Blood pressure that is too high
- Cholesterol levels that are high
- Infections that are serious
- Clots in the blood
- Problems with the immune system and cancer
- Heart and circulatory difficulties
- Tears in the intestines or stomach
Xeljanz Safety Warnings: Why Did the FDA Issue Them?
Premarketing clinical testing isn’t necessarily the end of drug safety testing. The FDA may authorize “post-marketing” safety studies, or continuing investigations, after approving a medicine. The FDA may issue stronger product warnings based on the findings of this testing to reflect the most recent safety facts.
The FDA mandated post-marketing studies when it initially authorized Xeljanz in 2012 to assess the risk of heart-related events, cancer, and infections. The FDA wanted to see how safe Xeljanz was in comparison to a TNF inhibitor (another type of anti-inflammatory drug). Because a postmarketing research indicated an increased risk of blood clots in the lungs and mortality, the FDA issued a Drug Safety Communication concerning Xeljanz in February 2019. The FDA looked into the matter further and eventually issued a new boxed warning for these adverse effects.
New findings from the post-marketing research prompted another FDA warning in February 2021, this time concerning Xeljanz’s elevated risk of significant heart-related issues and cancer. While the FDA has not yet published a new boxed warning for these adverse effects, Xeljanz patients are quite concerned.
Xeljanz and Blood Clots: What Are the Risks?
Thrombosis has been reported in individuals treated with Xeljanz, including pulmonary embolism (a blood clot that spreads to the lungs), deep venous thrombosis (a blood clot in a deep vein, generally the legs), and arterial thrombosis (a blood clot in an artery).
An examination of the Xeljanz post-marketing research indicated a higher frequency of blood clots in the lungs, according to the FDA. The result was for the Xeljanz 10 mg twice day dosage. Many of the blood clots were dangerous, and some even killed people. Blood clots may also lead to heart attacks, strokes, and organ damage.
What Are the Cancer Risks of Xeljanz?
Xeljanz patients have been diagnosed with lymphoma, melanoma, lung cancer, breast cancer, prostate cancer, pancreatic cancer, and other malignancies. In the post-marketing study, 164 of the 4,362 test volunteers got cancer. In February 2021, the FDA issued a public warning about the cancer risks associated with Xeljanz.
What Are the Consequences of Taking Xeljanz and Having Cardiovascular Problems?
The FDA issued a warning in February 2021 regarding significant cardiac issues associated to Xeljanz. Pfizer refers to them as “serious adverse cardiovascular events” in a news statement on the post-marketing study findings (MACE). A total of 135 individuals with MACE were included in the research. The 10 mg dosage caused somewhat more cardiovascular events than the 5 mg dose. A heart attack was the most often reported occurrence.
Cardiac arrest, cardiovascular mortality, ischemic stroke, acute coronary syndrome, heart failure, and atrial fibrillation are some of the other cardiovascular issues that Xeljanz might cause.
Is a Xeljanz Lawsuit Right for Me?
You’re undoubtedly asking why Pfizer was required to research the drug’s lethal side effects after it was licensed and made accessible to the public, just like other Xeljanz patients. Shouldn’t the corporation have issued warnings from the moment it went public if it was aware of such issues?
Our lawyers are aware of your worries and are here to assist you. We have a strong track record of taking on the pharmaceutical business and successfully recovering compensation for our customers. If you took Xeljanz and developed cancer, a heart condition, or a blood clot, you may be qualified for a Xeljanz lawsuit.
The initial stage in the legal procedure is a free consultation. Please fill out our contact form with your contact information and a short explanation of your situation, and a Xeljanz lawyer will contact you as soon as possible. You may also reach us at 855 696 0024 right now.
Xeljanz, a drug commonly prescribed for rheumatoid arthritis, is a type of medication called an immunosuppressant. It’s also known as tofacitinib citrate. The “fda” stands for the Food and Drug Administration, which is the United States government agency that regulates drugs. Reference: xeljanz, fda.
Frequently Asked Questions
What is xeljanz used for?
A: Xeljanz is used to treat psoriasis.
Is xeljanz an anti inflammatory?
A: No. xeljanz is not an anti-inflammatory drug, and it will not treat inflammation in the body.
What are the side effects of taking xeljanz?
A: Side effects of taking xeljanz may include nausea, diarrhea, headaches and vomiting. Stop taking the medication if you experience these side effects.
- xeljanz uses
- xeljanz side effects
- xeljanz lawsuit
- xeljanz manufacturer
- xeljanz reviews